Differential expression of alpha-synuclein isoforms in dementia with Lewy bodies

Neuropathol Appl Neurobiol. 2004 Dec;30(6):601-7. doi: 10.1111/j.1365-2990.2004.00572.x.

Abstract

Dementia with Lewy bodies (DLB) is characterized by the widespread presence of Lewy bodies (LBs) in the brain. alpha-Synuclein, the main component of LBs, is expressed as two main isoforms (112 and 140), but little is known about their differential expression in the brain. We compared alpha-synuclein 112 and alpha-synuclein 140 expression levels in the prefrontal cortices of six DLB patients, eight Alzheimer disease (AD) patients, and six control subjects. Relative alpha-synuclein 112 and alpha-synuclein 140 expression levels were determined by real-time polymerase chain reaction with competimer technology using a LightCycler System. Whereas total alpha-synuclein levels were just marginally elevated in DLB in comparison with the other groups, alpha-synuclein 112 was seen to be markedly increased in DLB compared with AD cases and controls. In contrast, alpha-synuclein 140 levels were significantly diminished in both neurodegenerative disorders in comparison with controls. These results show differential overexpression of alpha-synuclein 112 in DLB, a finding that could be of importance in DLB pathogenesis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Alzheimer Disease / metabolism
  • Brain Chemistry / physiology
  • DNA Primers
  • Female
  • Humans
  • Isomerism
  • Lewy Body Disease / metabolism*
  • Male
  • Middle Aged
  • Nerve Tissue Proteins / biosynthesis*
  • Prefrontal Cortex / metabolism
  • RNA, Messenger / biosynthesis
  • RNA, Messenger / isolation & purification
  • Reverse Transcriptase Polymerase Chain Reaction
  • Synucleins
  • alpha-Synuclein

Substances

  • DNA Primers
  • Nerve Tissue Proteins
  • RNA, Messenger
  • SNCA protein, human
  • Synucleins
  • alpha-Synuclein